Atlas Trials

A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

Clinical trial NCT05126966 · WITHDRAWN

Trial details

NCT number
NCT05126966
Sponsor
Hoffmann-La Roche
Status
WITHDRAWN
Phase
Phase 3
Study type
INTERVENTIONAL
Neovascular Age-Related Macular Degeneration
Start date
2023-12-29
Primary completion
2025-01-31
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.